References
- Abou-Alfa, G.K. and Venook, A.P., 2013. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? The lancet oncology, 14 (7), e283–e288.
- Balkwill, F., 2004. Cancer and the chemokine network. Nature reviews cancer, 4 (7), 540–550.
- Chalin, A., et al., 2018. Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injury. Cytokine, 111, 500–504.
- Feurino, L.W., et al., 2006. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer investigation, 24 (7), 696–703.
- Forner, A., 2015. Hepatocellular carcinoma surveillance with miRNAs. The lancet oncology, 16 (7), 743–745.
- Gu, X., et al., 2012a. An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population. Molecular biology reports, 39 (2), 797–803.
- Gu, X.L., et al., 2012b. Expression of CXCL14 and its anticancer role in breast cancer. Breast cancer research and treatment, 135 (3), 725–735.
- Hoeben, A., et al., 2004. Vascular endothelial growth factor and angiogenesis. Pharmacological reviews, 56 (4), 549–580.
- Ji, X., et al., 2018. CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection. Medicine (Baltimore), 97, e0101.
- Kim, T.K., et al., 2018. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a. Molecular oncology, 12 (3), 356–372.
- Komori, R., et al., 2010. Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine. Biomedical research (Tokyo, Japan), 31 (2), 123–131.
- Kurth, I., et al., 2001. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. Journal of experimental medicine, 194 (6), 855–861.
- Lyu, X.J., et al., 2015. Elevated S100A6 (Calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma. Oncotarget, 6 (9), 6656–6669.
- Nishida, N., et al., 2006. Angiogenesis in cancer. Vascular health and risk management, 2 (3), 213–219.
- Potente, M., Gerhardt, H., and Carmeliet, P., 2011. Basic and therapeutic aspects of angiogenesis. Cell, 146 (6), 873–887.
- Shellenberger, T.D., et al., 2004. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer research, 64 (22), 8262–8270.
- Sjoberg, E., et al., 2019. A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer. Clinical cancer research, 25, 3702–3717.
- Starnes, T., et al., 2006. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Experimental hematology, 34 (8), 1101–1105.
- Strieter, R.M., et al., 2004. CXC chemokines in angiogenesis of cancer. Seminars in cancer biology, 14 (3), 195–200.
- Strieter, R.M., et al., 2006. Cancer CXC chemokine networks and tumour angiogenesis. European journal of cancer (Oxford, England: 1990), 42 (6), 768–778.
- Wente, M.N., et al., 2008. CXCL14 expression and potential function in pancreatic cancer. Cancer letters, 259 (2), 209–217.
- Yin, R., et al., 2018. Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. International journal of biochemistry & cell biology, 97, 43–51.